Why Chemed’s Index Removals Matter for Investors

Chemed (CHE) has been dropped from several Russell growth oriented benchmarks, including the Russell 1000 Growth and Russell 3000 Growth indexes, an event that can influence passive fund flows and near term trading activity.

Despite Chemed’s removal from several Russell growth indexes, the stock’s recent trading has been firm, with a 1 month share price return of 9.91% and a 90 day share price return of 22.80%. However, the 1 year total shareholder return of 4.74% contrasts with weaker 3 and 5 year total shareholder returns.

If the index reshuffle has you thinking more broadly about opportunities, this could be a useful moment to scan other healthcare related ideas through the 40 healthcare AI stocks.

Chemed has just delivered a strong short term rebound while longer term returns look more muted. Are investors catching the early stages of a reset, or paying up after the easier gains have already shown up?

Most Popular Narrative: 2.9% Undervalued

The most followed Chemed narrative pegs fair value at $500.00, slightly above the last close of $485.37, suggesting only a modest valuation gap.

An aging US population and management’s intention to pursue additional hospice starts and acquisitions in certificate of need states increase the long term demand pool for VITAS services, which can support sustained growth in average daily census, revenue and earnings.

Want to understand why this narrative still sees upside from here? It hinges on steady revenue expansion, firmer margins, and a future earnings base that has to justify a lower multiple than today. Curious which specific profit and valuation assumptions need to line up for $500.00 to make sense?

Result: Fair Value of $500.00 (UNDERVALUED)

However, this Chemed narrative also depends on VITAS successfully shifting its admission mix without Medicare Cap issues returning, and on Roto Rooter managing paid digital lead costs and insurer scrutiny in water restoration.

Next Steps

If the mixed tone of Chemed’s recent performance and narrative leaves you undecided, treat that as your prompt to move quickly and check the underlying numbers and assumptions for yourself, then weigh both sides through the 2 key rewards and 1 important warning sign.

Looking for more Chemed sized investment ideas?

Chemed may be front of mind today, but your next opportunity could be waiting in a very different corner of the market, so do not leave that potential on the table.

• Target income potential with companies that offer robust payouts and consistency by scanning the 9 dividend fortresses.
• Hunt for quality at sensible prices by checking the 45 high quality undervalued stocks that filters for strong fundamentals and appealing valuations.
• Prioritise sleep at night stability by reviewing the 74 resilient stocks with low risk scores focused on businesses with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.